- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CORONA Remedies appoints four Independent Directors to its board

Ahmedabad: CORONA Remedies Limited, backed by Sepia Investments Limited, an affiliate of ChrysCapital, has appointed Ameetkumar Hiranyakumar Desai, Bhaskar Vemban Iyer, Shirish Gundopant Belapure and Monica Hemal Kanuga as Independent Directors to its Board of Directors bringing in diverse expertise and experience.
Ameet is founder and director of Anubhuti Advisory LLP. He has distinguished career spanning more than 35 years with India Inc. He has an extensive experience in Treasury, Investment Management and Corporate Finance. He was the Executive Director and group CFO with Adani Group. Ameet was Global Head of M&A and Business Planning for Ranbaxy Laboratories Ltd., the largest Indian pharmaceutical company.
Bhasker is a strategic business leader with over four decades of experience in the pharmaceutical and healthcare industry spanning country management, global leadership and Board Directorship roles. Prior to joining Advent as an Operating Partner in a specialist advisory capacity, Bhasker was a Corporate Officer with Abbott for the India region, leading sales, manufacturing and R&D operations for the healthcare MNC in India. He has held global leadership positions with Wockhardt in India and AstraZeneca in Asia-Pacific based in Singapore and country management positions in AstraZeneca, Nicholas Piramal India Limited, ICI Pharmaceuticals and senior roles in Glaxo India Limited. He is also a Director, Value Optimisation Board for Quadria Capital, a healthcare focused PE firm. He is also an Independent Director on the Boards of RPG Life Science, Cohance Lifesciences Ltd, and Themis Medicare Ltd. He is also Director at Quadria Capital, a private equity firm.
Shirish is a Senior Technical Advisor with Indian Pharmaceutical Alliance since April ‘19. He has an experience of managing operations in Pharmaceuticals in the wide range of areas like formulations/Api manufacturing & development, Quality Assurance, Regulatory affairs for about 42 years. He is also Venture Partner with “Eight Roads”, a private equity firm. He was also president of PDA India chapter for two years from Dec ‘19 to Nov ’21. Prior to this, he was Managing Director of Zydus Hospira Oncology Pvt Ltd- a joint venture company between Zydus & Pfizer. Earlier experience includes working as President (Global Manufacturing) and was responsible for entire manufacturing network of Formulations and Projects globally for Zydus Cadila. In addition to this, he has also worked with Sun Pharma, Cipla, Lederle to name a few, in various capacities. He was associated with Nirma University as a member of board of studies. He is also on the board of directors in multiple companies to name a few, Albert David, Jubiliant Pharmanova etc.
Niravkumar Kirtikumar Mehta, Managing Director and CEO of CORONA Remedies, said, "We welcome these distinguished professionals to our Board. Their breadth of experience and strategic insight will support our mission of delivering impactful healthcare solutions and upholding high governance standards."
Ameetkumar Hiranyakumar Desai, said, "I joined the Board of CORONA Remedies, where I will contribute my experience and insights to support the Company's growth and strategic objectives."
Bhaskar Vemban Iyer added, "I joined the Board of CORONA Remedies committed to leveraging my industry insights to drive sustainable growth and build long-term stakeholder value. I will use my industry experience to support the Company’s sustainable growth and long-term value creation."
Shirish Gundopant Belapure expressed by stating, I joined the board of "CORONA Remedies and will contribute to its success through operational excellence and innovation providing guidance on key appointments and succession planning, aligned with Company’s long-term vision and sustainability."
Monica Hemal Kanuga stated, "I will contribute to the Board of CORONA Remedies, supporting the Company's focus on innovation and patient-centric solutions."
CORONA Remedies Limited is an India-focused branded pharmaceutical formulation Company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
The Company has two manufacturing facilities, located in the states of Gujarat and Himachal Pradesh and it is in the process of commissioning a hormone manufacturing facility in Gujarat at Ahmedabad.
As of December 31, 2024, it had a workforce of 4470 with two facilities which are spread over an aggregate of 2.83 hectares and have an aggregate installed capacity for formulations of 1,285.44 million units per annum, with a total of 11 production lines.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751